Assis, Ana B.

Brudvig, Jon

Cooper, Jonathan D.

Davis, Samantha

Johnson, Tyler B.

Kaspar, Brian K.

Likhite, Shibi

Lu, Bin

Meyer, Kathrin

Nelvagal, Hemanth R.

Poole, Timothy A.

Pratt, Melissa A.

Wang, Shaomei

Weimer, Jill M.

White, Katherine A.

English

Digital Commons@Becker

OMTM, Volume 20Supplemental InformationIntracranial delivery of AAV9 gene therapypartially prevents retinal degenerationand visual deficits in CLN6-Batten disease miceKatherine A. White, Hemanth R. Nelvagal, Timothy A. Poole, Bin Lu, Tyler B.Johnson, Samantha Davis, Melissa A. Pratt, Jon Brudvig, Ana B. Assis, ShibiLikhite, Kathrin Meyer, Brian K. Kaspar, Jonathan D. Cooper, Shaomei Wang, and JillM. WeimerFigure S1. Wildtype and Cln6nclf control show limited hCLN6 RNAscope expression, while AAV9treated Cln6nclf animal shows robust hCLN6 expression (purple). Shown in brain tissue.Figure S2. Representative whole-mount image of scAAV9 treated animal shows primarily central retinal expressionwhen immunolabeled with an anti-hCLN6 antibody (red). 

Intracranial delivery of AAV9 gene therapy partially prevents retinal degeneration and visual deficits in CLN6-Batten disease mice

https://digitalcommons.wustl.edu/cgi/viewcontent.cgi?filename=0&article=11102&context=open_access_pubs&type=additional

Intracranial delivery of AAV9 gene therapy partially prevents retinal degeneration and visual deficits in CLN6-Batten disease mice

Abstract

Similar works

Full text

Available Versions

Digital Commons@Becker